Otsuka Pharmaceutical (TYO; 4578) has decided jointly with fellow Japanese firm Takara Bio (TYO: 4974) to terminate agreements on co-development and exclusive marketing of the drug candidates oncolytic virus HF10 (development code: TBI-1401, INN: canerpaturev and CD19-targeted CAR gene therapies (development code: TBI-1501).
Otsuka and Takara Bio will continue to co-develop NY-ESO-1 siTCR gene therapy product (development code: TBI-1301).
Oncolytic virus HF10
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze